Minerva Neurosciences, Inc. (NASDAQ:NERV) Sees Significant Growth in Short Interest

Minerva Neurosciences, Inc. (NASDAQ:NERV) was the target of a significant growth in short interest during the month of November. As of November 15th, there was short interest totalling 23,400 shares, a growth of 229.6% from the October 31st total of 7,100 shares. Approximately 0.4% of the shares of the stock are short sold. Based on an average trading volume of 16,100 shares, the short-interest ratio is currently 1.5 days.

Minerva Neurosciences Stock Performance

NASDAQ:NERV traded down $0.02 during midday trading on Wednesday, reaching $2.15. 26,674 shares of the stock traded hands, compared to its average volume of 51,652. The stock has a market capitalization of $15.03 million, a P/E ratio of -4.89 and a beta of 0.18. The company has a fifty day moving average of $2.48 and a 200 day moving average of $2.77. Minerva Neurosciences has a 12 month low of $2.07 and a 12 month high of $13.49.

Analyst Ratings Changes

A number of equities analysts recently commented on NERV shares. HC Wainwright reiterated a “neutral” rating and issued a $5.00 target price on shares of Minerva Neurosciences in a research report on Wednesday, November 6th. StockNews.com began coverage on Minerva Neurosciences in a research note on Tuesday. They issued a “sell” rating for the company.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.